Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to >95% mean increase in progranulin levels in CSF, compared to baseline Topline results indicate VES001 normalises levels of progranulin in people who have a shortage of this vital protein for genetic reasons, potentially stopping them developing symptomatic frontotemporal dementia (FTD) […]
Copenhagen, Denmark, 01 July 2025 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech developing an oral therapy for frontotemporal dementia, today announces the appointment of Jacob Falck Hansen as Chief Executive Officer (CEO). Jacob Falck Hansen brings more than 15 years of leadership experience from the pharmaceutical and biotech industry. He […]
VES001 is a first-in-class oral, brain penetrant, small molecule sortilin inhibitor for treatment of FTD(GRN) Data demonstrate excellent safety, tolerability profile, dose-proportionality and target engagement with elevations in progranulin in both plasma and CNS CTA filed for Phase IIa study, first dose targeted for Q4 2024 Copenhagen, Denmark, 04 September 2024 – Vesper Bio ApS […]
Copenhagen, Denmark, 30 May 2024 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech and world leader in sortilin receptor biology, today announces completion of the single ascending dose stage of its first-in-human trial of VES001 in healthy volunteers. VES001 is the first oral, brain penetrant, small molecule sortilin inhibitor designed as […]
Vesper Bio, backed by Lundbeckfonden BioCapital, initiates a Phase I study to evaluate its lead asset VES001, for the treatment of FTD (GRN mutation), addressing a critical unmet medical need VES001 is a product designed with the needs of the patients and their care givers in mind The Phase I study will assess safety, tolerability […]
